Company Overview
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Why Investors Should Care
Trades at a P/E of 0.1, below the sector median of 24.8.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -95.55% |
| 6 Months: | -61.73% |
| 3 Months: | -69.63% |
| 1 Month: | +82.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.74 · Neutral
P/E of 0.05 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 95.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MBRX Moleculin Biotech, Inc. PHARMA | 0.75 | 0.05 | $14.61M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -222.75K | -321.00K | -724.00K | -1.42M | -1.53M | -1.32M | -2.40M | -2.64M | -5.46M | -2.59M | -4.57M | -3.63M | -4.51M | -5.06M | -5.03M | -6.15M | -6.09M | -5.52M | -6.16M | -7.07M | -7.43M | -9.08M | -8.35M | -6.41M | -5.95M | -6.68M | -6.18M | -7.13M | -5.94M | -5.72M | -5.91M | -7.87M |
| Net Income | -224.31K | -332.00K | -739.00K | -1.43M | -329.00K | -3.42M | -2.87M | -1.93M | -5.12M | -2.04M | -4.04M | -1.22M | -4.14M | -1.21M | -10.11M | -3.40M | -4.45M | -4.24M | -4.38M | -6.87M | -6.78M | -8.61M | -7.92M | -5.98M | -5.61M | -6.42M | -6.01M | -7.02M | -5.90M | -17.81M | -25.40M | -12.85M |
| R&D Expense | 38.41K | 15.00K | 105.00K | 497.00K | 683.00K | 515.00K | 1.06M | 1.24M | 4.23M | 1.33M | 2.93M | 2.10M | 2.79M | 3.21M | 3.33M | 4.43M | 4.11M | 3.04M | 4.09M | 4.62M | 4.20M | 5.96M | 5.69M | 3.89M | 3.28M | 4.25M | 4.09M | 4.93M | 3.44M | 3.60M | 3.74M | 5.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.88M | -8.65M | -15.03M | -17.52M | -19.74M | -22.97M | -30.64M | -29.63M | -26.64M | -25.10M |
| Net Income | -3.93M | -9.80M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -26.05M | -33.56M |
| R&D Expense | 1.50M | 4.54M | 9.73M | 11.01M | 12.76M | 14.42M | 18.97M | 19.49M | 17.73M | 15.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2015 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 28.09K | 16.39M | 19.48M | 19.59M | 25.23M | 29.03M | 84.09M | 57.42M | 38.22M | 16.93M | 22.13M |
| Total Equity | - | -745.00K | 14.96M | 17.12M | 14.27M | 15.57M | 17.76M | 78.99M | 52.19M | 30.93M | 11.21M | 15.01M |
| Cash & Equivalents | 0 | 28.00K | 5.01M | 7.71M | 7.13M | 10.73M | 15.17M | 70.90M | 43.15M | 23.55M | 4.28M | 8.88M |
| Total Liabilities | - | 772.79K | 1.43M | 2.37M | 5.31M | 9.66M | 11.27M | 5.10M | 5.23M | 12.14M | 5.72M | 7.12M |
| Current Liabilities | - | 772.79K | 1.34M | 2.21M | 3.88M | 3.57M | 2.92M | 3.62M | 4.82M | 6.82M | 5.36M | 6.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.77M | -7.32M | -12.20M | -17.20M | -17.77M | -18.95M | -27.64M | -23.59M | -23.86M | -22.73M |
| Investing Cash Flow | -121.00K | -28.00K | -417.00K | -51.00K | -374.00K | -19.00K | -67.00K | -124.00K | -13.00K | 0 |
| Financing Cash Flow | 8.87M | 10.06M | 12.04M | 20.85M | 22.55M | 74.72M | -23.00K | 4.14M | 4.63M | 27.28M |
| Capital Expenditure | -21.00K | -28.00K | -417.00K | -52.00K | -376.00K | -19.00K | -67.00K | -124.00K | -13.00K | -0 |
| Free Cash Flow | -3.79M | -7.35M | -12.62M | -17.25M | -18.15M | -18.97M | -27.71M | -23.71M | -23.88M | -22.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -26.2% | -57.3% | -83.2% | -84.8% | -97.7% | -20.1% | -55.6% | -96.3% | -232.4% | -223.6% |
| ROCE % | -25.8% | -50.1% | -95.7% | -80.9% | -75.6% | -28.5% | -58.2% | -94.4% | -230.3% | -164.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.24% | 47.25K | $36.53K |
| 2 | Vanguard Capital Management LLC | 0.22% | 42.22K | $32.64K |
| 3 | Vanguard Fiduciary Trust Co | 0.15% | 29.88K | $23.10K |
| 4 | Xtx Topco Ltd | 0.12% | 22.94K | $17.74K |
| 5 | Morgan Stanley | 0.10% | 20.04K | $15.49K |
| 6 | Rockefeller Capital Management L.P. | 0.08% | 15.00K | $11.60K |
| 7 | Tower Research Capital LLC (TRC) | 0.02% | 3.51K | $2.72K |
| 8 | Citigroup Inc. | 0.01% | 2.67K | $2.07K |
| 9 | Blackrock Inc. | - | 491 | $379 |
| 10 | Barclays Plc | - | 621 | $480 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBRX
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1nWGFQVFNHSkloX05rbFNHQWZ6MGk4Ump0UWk5TkNWOGxlSU9LWUdHM1VXVksyZEQwcVA4eVhuMVVnbFZiUE9scg?oc=5" target="_blank">Moleculin Biotech Stock Price Forecast. Should You Buy MBRX?</a> …
Moleculin Biotech Stock Is Sinking Friday: What's Going On? - Moleculin Biotech (NASDAQ:MBRX) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQcTdncHI0R0JqWDZZWDNXS1M3WnpnOHJtcVJXRnBwRU5uLXRlbGNuX29nS0E5LXpzTkU4ZVBTVWh1aHJqdElfdTB4cFl0b3BmaWktTGtxSVhyT0gyWmduQUVTTGVZZGRzUkZCZnZfWFdHWUx4eDQwZkpaY0Q3TFhiSTNCc0pfdm1DRGRLZk…
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNTkpoRVh6M1gxcTRyeHdSc3JqalpROHA0aUZBR1hwZEZ3TmlDVThZcFdXdnhDSllNSUQ0cl91UlQ3SHZJLTFjd1UzOTlpbE9ETVBjZ3BiaDVzT1ZNcDVsU0FBWVJUeU1QLU1YNHhsdUduc0FUYmF6UXktYTF1dmc5MzBRTWJMWGs0d0pQSn…
LUNR, FLY Stock Gains on Winning NASA Lunar Contracts In Moon Base Project - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNRlJ0ei1CSzl2NEhaZHA3ZmJmdHc2d0R6SWVWRFRrWWpWZlRZYWdsZ3dtNHI5aXgxU3JoSWtGNzdDc09oS2dIRWhMV19sSm9PSGNfNmp0SDUwanBiYy1IRUlQU1F3bEowYkJIRmJpTDFNUE5KVkY4SEN3RVpfZ0VlVlVNbFR6a0hCZWQ4Yz…
Moleculin (NASDAQ: MBRX) posts investor presentation online - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPVTAxaUdmZ1dhZ2ZyX3d6X3N6TWpOSWxUWWZTNVBlMDRoMWhPcVlBMl9fQ3BkMVluUjU4WUJ5UlRQdVRkNmg0S0JJSmNvMTdMVE9pSmw5N1NpSVREVGFZTnJ0bjZfN0xYOTg4TFl2ckdCVEtQZ3pKeEFINV9peVcxNXJ3RlphelBsVmNtaz…
Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQXzBCRUREcDlWY0c1eXFTMDlSWUQydGFPdUFkTnFlclRqdV9sRnF3R0ZGOGp0aWZEWnhMaTdXcnVuQXV4cDdkbklQMEJXOFo3NFFqam16ZC1vTXVOcWwxX0pfNEEtenNaZ1RKZVlQcUtTdHc2MzF1T2tGMllYMVMtWEZ0dG1aZWszLTBBZl…
MBRX — Frequently Asked Questions
What is the current share price of Moleculin Biotech, Inc. (MBRX)?
As of 2026-09-19 21:16 PDT, Moleculin Biotech, Inc. (MBRX) trades at $0.75 on NasdaqCM. Its 52-week range is $0.38 to $17.08.
What is the market capitalisation of MBRX?
Moleculin Biotech, Inc. (MBRX) has a market capitalisation of $14.61M on NasdaqCM.
What is the P/E ratio of MBRX?
MBRX trades at a trailing price-to-earnings (P/E) ratio of 0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.47.
Is MBRX a good stock to buy?
This page provides a data-driven analysis of Moleculin Biotech, Inc. (MBRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.